Evolution and Future of Growth Plate Therapeutics

https://doi.org/10.1159/000328117

2.

Lui

JC

,

Nilsson

O

,

Baron

J

.

Growth plate senescence and catch-up growth

.

Endocr Dev

.

2011

;

21

:

23

–

9

.

.

https://doi.org/10.1096/fasebj.13.14.1985

3.

Wang

J

,

Zhou

J

,

Bondy

CA

.

IGF1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy

.

FASEB J

.

1999

;

13

(

14

):

1985

–

90

.

.

4.

Nilsson

O

,

Marino

R

,

De Luca

F

,

Phillip

M

,

Baron

J

.

Endocrine regulation of the growth plate

.

Horm Res

.

2005

;

64

(

4

):

157

–

65

.

5.

Oz

OK

,

Millsaps

R

,

Welch

R

,

Birch

J

,

Zerwekh

JE

.

Expression of aromatase in the human growth plate

.

J Mol Endocrinol

.

2001

;

27

(

2

):

249

–

53

.

6.

Abu

EO

,

Horner

A

,

Kusec

V

,

Triffitt

JT

,

Compston

JE

.

The localization of androgen receptors in human bone

.

J Clin Endocrinol Metab

.

1997

;

82

(

10

):

3493

–

7

.

7.

Keenan

BS

,

Richards

GE

,

Ponder

SW

,

Dallas

JS

,

Nagamani

M

,

Smith

ER

,

Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty

.

J Clin Endocrinol Metab

.

1993

;

76

(

4

):

996

–

1001

.

8.

Stevens

DA

,

Hasserjian

RP

,

Robson

H

,

Siebler

T

,

Shalet

SM

,

Williams

GR

.

Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation

.

J Bone Miner Res

.

2000

;

15

(

12

):

2431

–

42

.

https://doi.org/10.1038/nrendo.2013.5

9.

Mazziotti

G

,

Giustina

A

.

Glucocorticoids and the regulation of growth hormone secretion

.

Nat Rev Endocrinol

.

2013

;

9

(

5

):

265

–

76

.

.

10.

Allen

DB

,

Julius

JR

,

Breen

TJ

,

Attie

KM

.

Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study

.

J Clin Endocrinol Metab

.

1998

;

83

(

8

):

2824

–

9

.

https://doi.org/10.1159/000321244

11.

Lui

JC

,

Baron

J

.

Effects of glucocorticoids on the growth plate

.

Endocr Dev

.

2011

;

20

:

187

–

93

.

.

12.

Marino

R

,

Hegde

A

,

Barnes

KM

,

Schrier

L

,

Emons

JA

,

Nilsson

O

,

Catch-up growth after hypothyroidism is caused by delayed growth plate senescence

.

Endocrinology

.

2008

;

149

(

4

):

1820

–

8

.

https://doi.org/10.1159/000455968

13.

Shalitin

S

,

Kiess

W

.

Putative effects of obesity on linear growth and puberty

.

Horm Res Paediatr

.

2017

;

88

(

1

):

101

–

10

.

.

14.

Nakajima

R

,

Inada

H

,

Koike

T

,

Yamano

T

.

Effects of leptin to cultured growth plate chondrocytes

.

Horm Res

.

2003

;

60

(

2

):

91

–

8

.

15.

Masarwi

M

,

Shamir

R

,

Phillip

M

,

Gat-Yablonski

G

.

Leptin stimulates aromatase in the growth plate: limiting catch-up growth efficiency

.

J Endocrinol

.

2018

;

237

(

3

):

229

–

42

.

https://doi.org/10.1016/S2352-4642(18)30306-7

16.

Reinehr

T

,

Roth

CL

.

Is there a causal relationship between obesity and puberty?

Lancet Child Adolesc Health

.

2019

;

3

(

1

):

44

–

54

.

.

https://doi.org/10.3389/fendo.2011.00113

17.

Karimian

E

,

Chagin

AS

,

Sävendahl

L

.

Genetic regulation of the growth plate

.

Front Endocrinol

.

2012

;

2

:

113

.

.

18.

Collett-Solberg

PF

,

Jorge

AAL

,

Boguszewski

MCS

,

Miller

BS

,

Choong

CSY

,

Cohen

P

,

Growth hormone therapy in children; research and practice: a review

.

Growth Horm IGF Res

.

2019

;

44

:

20

–

32

.

https://doi.org/10.1210/jc.2004-2187

19.

Stephure

DK

.

Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial

.

J Clin Endocrinol Metab

.

2005

;

90

(

6

):

3360

–

6

.

.

20.

van Pareren

YK

,

de Muinck Keizer-Schrama

SMPF

,

Stijnen

T

,

Sas

TCS

,

Jansen

M

,

Otten

BJ

,

Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens

.

J Clin Endocrinol Metab

.

2003

;

88

(

3

):

1119

–

25

.

21.

Gravholt

CH

,

Andersen

NH

,

Conway

GS

,

Dekkers

OM

,

Geffner

ME

,

Klein

KO

,

Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

.

Eur J Endocrinol

.

2017

;

177

(

3

):

G1

–

g70

.

22.

Murphy

N

,

Knuppel

A

,

Papadimitriou

N

,

Martin

RM

,

Tsilidis

KK

,

Smith-Byrne

K

,

Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women

.

Ann Oncol

.

2020

;

31

(

5

):

641

–

9

.

23.

Larsson

SC

,

Carter

P

,

Vithayathil

M

,

Kar

S

,

Mason

AM

,

Burgess

S

.

Insulin-like growth factor-1 and site-specific cancers: a Mendelian randomization study

.

Cancer Med

.

2020

;

9

(

18

):

6836

–

42

.

https://doi.org/10.17458/per.vol16.2018.dmb.ghshortchilbornsmall

24.

de Andre Cardoso-Demartini

A

,

Malaquias

AC

,

da Silva Boguszewski

MC

.

Growth hormone treatment for short children born small for gestational age

.

Pediatr Endocrinol Rev

.

2018

;

16

(

Suppl 1

):

105

–

12

.

.

25.

Smeets

CC

,

Zandwijken

GRJ

,

Renes

JS

,

Hokken-Koelega

ACS

.

Long-term results of GH treatment in silver-russell syndrome (SRS): do they benefit the same as non-SRS short-SGA?

J Clin Endocrinol Metab

.

2016

;

101

(

5

):

2105

–

12

.

https://doi.org/10.1016/j.ecl.2006.11.006

26.

Quigley

CA

.

Growth hormone treatment of non-growth hormone-deficient growth disorders

.

Endocrinol Metab Clin North Am

.

2007

;

36

(

1

):

131

–

86

.

.

27.

van Gool

SA

,

Kamp

GA

,

Visser-van Balen

H

,

Mul

D

,

Waelkens

JJJ

,

Jansen

M

,

Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty

.

J Clin Endocrinol Metab

.

2007

;

92

(

4

):

1402

–

8

.

28.

Ranke

MB

,

Lindberg

A

,

Carlsson

M

,

Camacho-Hübner

C

,

Rooman

R

.

Treatment with growth hormone in noonan syndrome observed during 25 years of KIGS: near adult height and outcome prediction

.

Horm Res Paediatr

.

2019

;

91

(

1

):

46

–

55

.

29.

Gahunia

HK

,

Babyn

PS

,

Kirsch

S

,

Mendoza-Londono

R

.

Imaging of SHOX-associated anomalies

.

Semin Musculoskelet Radiol

.

2009

;

13

(

3

):

236

–

54

.

30.

Shima

H

,

Tanaka

T

,

Kamimaki

T

,

Dateki

S

,

Muroya

K

,

Horikawa

R

,

Systematic molecular analyses of SHOX in Japanese patients with idiopathic short stature and Leri-Weill dyschondrosteosis

.

J Hum Genet

.

2016

;

61

(

7

):

585

–

91

.

31.

Wolters

B

,

Lass

N

,

Wunsch

R

,

Böckmann

B

,

Austrup

F

,

Reinehr

T

.

Short stature before puberty: which children should be screened for SHOX deficiency?

Horm Res Paediatr

.

2013

;

80

(

4

):

273

–

80

.

32.

Blum

WF

,

Ross

JL

,

Zimmermann

AG

,

Quigley

CA

,

Child

CJ

,

Kalifa

G

,

GH treatment to final height produces similar height gains in patients with SHOX deficiency and Turner syndrome: results of a multicenter trial

.

J Clin Endocrinol Metab

.

2013

;

98

(

8

):

E1383

–

92

.

33.

Leschek

EW

,

Rose

SR

,

Yanovski

JK

,

Troendle

JF

,

Quigley

CA

,

Chipman

JJ

,

Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial

.

J Clin Endocrinol Metab

.

2004

;

89

(

7

):

3140

–

8

.

34.

Scalco

RC

,

Melo

SSJ

,

Pugliese-Pires

PN

,

Funari

MFA

,

Nishi

MY

,

Arnhold

IJP

,

Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency

.

J Clin Endocrinol Metab

.

2010

;

95

(

1

):

328

–

32

.

35.

Carrel

AL

,

Myers

SE

,

Whitman

BY

,

Allen

DB

.

Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study

.

J Clin Endocrinol Metab

.

2002

;

87

(

4

):

1581

–

5

.

https://doi.org/10.1007/s004670000334

36.

Daughaday

WH

.

Growth hormone axis overview – somatomedin hypothesis

.

Pediatr Nephrol

.

2000

;

14

(

7

):

537

–

40

.

.

https://doi.org/10.1210/endo-97-4-780

37.

Phillips

LS

,

Herington

AC

,

Daughaday

WH

.

Steroid hormone effects on sonatomedin. I. Somatomedin action in vitro

.

Endocrinology

.

1975

;

97

(

4

):

780

–

6

.

.

38.

Salmon

WD

Jr,

Daughaday

WH

.

The importance of amino acids as dialyzable components of rat serum which promote sulfate uptake by cartilage from hypophysectomized rats in vitro

.

J Lab Clin Med

.

1958

;

51

(

2

):

107

–

73

.

39.

Rotwein

P

,

William

H

.

William H. Daughaday and the foundations of modern research into growth hormone and the insulin-like growth factors

.

Pediatr Endocrinol Rev

.

2013

;

10

(

3

):

280

–

3

.

https://doi.org/10.1111/j.1432-0436.1985.tb00316.x

40.

Green

H

,

Morikawa

M

,

Nixon

T

.

A dual effector theory of growth-hormone action

.

Differentiation

.

1985

;

29

(

3

):

195

–

8

.

.

41.

Wang

J

,

Zhou

J

,

Cheng

CM

,

Kopchick

JJ

,

Bondy

CA

.

Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth

.

J Endocrinol

.

2004

;

180

(

2

):

247

–

55

.

https://doi.org/10.1210/en.2014-1983

42.

Wu

S

,

Yang

W

,

De Luca

F

.

Insulin-like growth factor-independent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth

.

Endocrinology

.

2015

;

156

(

7

):

2541

–

51

.

.

https://doi.org/10.1016/j.ghir.2020.01.001

43.

Backeljauw

P

.

Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency

.

Growth Horm IGF Res

.

2020

;

51

:

22

–

6

.

.

44.

Backeljauw

PF

,

Kuntze

J

,

Frane

J

,

Calikoglu

AS

,

Chernausek

SD

.

Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I

.

Horm Res Paediatr

.

2013

;

80

(

1

):

47

–

56

.

45.

Lui

JC

,

Colbert

M

,

Cheung

CSF

,

Ad

M

,

Lee

A

,

Zhu

Z

,

Cartilage-targeted IGF-1 treatment to promote longitudinal bone growth

.

Mol Ther

.

2019

;

27

(

3

):

673

–

80

.

46.

Carel

JC

,

Eugster

EA

,

Rogol

A

,

Ghizzoni

L

,

Palmert

MR

;

ESPE-LWPES GnRH Analogs Consensus Conference Group

;

Consensus statement on the use of gonadotropin-releasing hormone analogs in children

.

Pediatrics

.

2009

;

123

(

4

):

e752

–

62

.

47.

Comite

F

,

Cassorla

F

,

Barnes

KM

,

Hench

KD

,

Dwyer

A

,

Skerda

MC

,

Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height

.

JAMA

.

1986

;

255

(

19

):

2613

–

6

.

48.

Pescovitz

OH

,

Comite

F

,

Hench

K

,

Barnes

K

,

McNemar

A

,

Foster

C

,

The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy

.

J Pediatr

.

1986

;

108

(

1

):

47

–

54

.

49.

Bangalore Krishna

K

,

Fuqua

JS

,

Rogol

AD

,

Klein

KO

,

Popovic

J

,

Houk

CP

,

Use of gonadotropin-releasing hormone analogs in children: update by an international consortium

.

Horm Res Paediatr

.

2019

;

91

(

6

):

357

–

72

.

https://doi.org/10.1159/000491103

50.

Kaplowitz

PB

,

Backeljauw

PF

,

Allen

DB

.

Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty

.

Horm Res Paediatr

.

2018

;

90

(

1

):

1

–

7

.

.

https://doi.org/10.4274/jcrpe.2017.S004

51.

Bereket

A

.

A critical appraisal of the effect of gonadotropin-releasing hormon analog treatment on adult height of girls with central precocious puberty

.

J Clin Res Pediatr Endocrinol

.

2017

;

9

(

Suppl 2

):

33

–

48

.

.

https://doi.org/10.1210/jcem.84.2.5430

52.

Palmert

MR

,

Malin

HV

,

Boepple

PA

.

Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients

.

J Clin Endocrinol Metab

.

1999

;

84

(

2

):

415

–

23

.

.

53.

Pasquino

AM

,

Pucarelli

I

,

Accardo

F

,

Demiraj

V

,

Segni

M

,

Di Nardo

R

.

Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function

.

J Clin Endocrinol Metab

.

2008

;

93

(

1

):

190

–

5

.

54.

Wilson

DM

,

McCauley

E

,

Brown

DR

,

Dudley

R

.

Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group

.

Pediatrics

.

1995

;

96

(

6

):

1095

–

100

.

55.

Schroor

EJ

,

van Weissenbruch

MM

,

Knibbe

P

,

Delemarre-van de Waal

HA

.

The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty

.

Eur J Pediatr

.

1995

;

154

(

12

):

953

–

7

.

56.

Poyrazoğlu

S

,

Günöz

H

,

Darendeliler

F

,

Saka

N

,

Bundak

R

,

Baş

F

.

Constitutional delay of growth and puberty: from presentation to final height

.

J Pediatr Endocrinol Metab

.

2005

;

18

(

2

):

171

–

9

.

57.

Arrigo

T

,

Cisternino

M

,

De

FL

,

Saggese

G

,

Messina

MF

,

Pasquino

AM

,

Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty

.

J Pediatr Endocrinol Metab

.

1996

;

9

(

5

):

511

–

7

.

58.

Malhotra

A

,

Poon

E

,

Tse

WY

,

Pringle

PJ

,

Hindmarsh

PC

,

Brook

CG

.

The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty

.

Clin Endocrinol

.

1993

;

38

(

4

):

393

–

8

.

59.

Gault

EJ

,

Cole

TJ

,

Casey

S

,

Hindmarsh

PC

,

Betts

P

,

Dunger

DB

,

Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial

.

Arch Dis Child

.

2021

;

106

(

1

):

74

–

6

.

https://doi.org/10.1056/NEJMcp1213178

60.

Allen

DB

,

Cuttler

L

.

Clinical practice. Short stature in childhood – challenges and choices

.

N Engl J Med

.

2013

;

368

(

13

):

1220

–

8

.

.

https://doi.org/10.1016/s0960-0760(97)80005-2

61.

Cutler

GB

Jr.

The role of estrogen in bone growth and maturation during childhood and adolescence

.

J Steroid Biochem Mol Biol

.

1997

;

61

(

3–6

):

141

–

4

.

.

62.

Ross

JL

,

Quigley

CA

,

Cao

D

,

Feuillan

P

,

Kowal

K

,

Chipman

JJ

,

Growth hormone plus childhood low-dose estrogen in Turner’s syndrome

.

N Engl J Med

.

2011

;

364

(

13

):

1230

–

42

.

63.

Bierich

JR

.

Estrogen treatment of girls with constitutional tall stature

.

Pediatrics

.

1978

;

62

(

6 Pt 2

):

1196

–

201

.

64.

Venn

A

,

Hosmer

T

,

Hosmer

D

,

Bruinsma

F

,

Jones

P

,

Lumley

J

,

Oestrogen treatment for tall stature in girls: estimating the effect on height and the error in height prediction

.

Clin Endocrinol

.

2008

;

68

(

6

):

926

–

9

.

65.

Hendriks

AE

,

Drop

SLS

,

Laven

JSE

,

Boot

AM

.

Fertility of tall girls treated with high-dose estrogen, a dose-response relationship

.

J Clin Endocrinol Metab

.

2012

;

97

(

9

):

3107

–

14

.

66.

Venn

A

,

Bruinsma

F

,

Werther

G

,

Pyett

P

,

Baird

D

,

Jones

P

,

Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility

.

Lancet

.

2004

;

364

(

9444

):

1513

–

8

.

https://doi.org/10.1001/archpedi.160.10.1035

67.

Lee

JM

,

Howell

JD

.

Tall girls: the social shaping of a medical therapy

.

Arch Pediatr Adolesc Med

.

2006

;

160

(

10

):

1035

–

9

.

.

https://doi.org/10.1136/archdischild-2015-309130

68.

Pollock

AJ

,

Fost

N

,

Allen

DB

.

Growth attenuation therapy: practice and perspectives of paediatric endocrinologists

.

Arch Dis Child

.

2015

;

100

(

12

):

1185

.

.

https://doi.org/10.1210/edrv.19.5.0345

69.

Drop

SL

,

De Waal

WJ

,

De Muinck Keizer-Schrama

SM

.

Sex steroid treatment of constitutionally tall stature

.

Endocr Rev

.

1998

;

19

(

5

):

540

–

58

.

.

https://doi.org/10.1001/archpedi.160.10.1013

70.

Gunther

DF

,

Diekema

DS

.

Attenuating growth in children with profound developmental disability: a new approach to an old dilemma

.

Arch Pediatr Adolesc Med

.

2006

;

160

(

10

):

1013

–

7

.

.

https://doi.org/10.1056/NEJM200210103471522

71.

Wolthers

OD

,

Allen

DB

.

Inhaled corticosteroids, growth, and compliance

.

N Engl J Med

.

2002

;

347

(

15

):

1210

–

1

.

.

72.

Allen

DB

,

Kappy

M

,

Diekema

D

,

Fost

N

.

Growth-attenuation therapy: principles for practice

.

Pediatrics

.

2009

;

123

(

6

):

1556

–

61

.

73.

Börjesson

AE

,

Windahl

SH

,

Karimian

E

,

Eriksson

EE

,

Lagerquist

MK

,

Engdahl

C

,

The role of estrogen receptor-α and its activation function-1 for growth plate closure in female mice

.

Am J Physiol Endocrinol Metab

.

2012

;

302

(

11

):

E1381

–

9

.

74.

Estrada

A

,

Boyce

AM

,

Brillante

BA

,

Guthrie

LC

,

Gafni

RI

,

Collins

MT

.

Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome

.

Eur J Endocrinol

.

2016

;

175

(

5

):

477

–

83

.

https://doi.org/10.1016/j.yapd.2017.03.004

75.

Lanes

R

,

González Briceño

LG

.

Alternatives in the treatment of short stature

.

Adv Pediatr

.

2017

;

64

(

1

):

111

–

31

.

.

76.

Ramchand

SK

,

Cheung

Y-M

,

Yeo

B

,

Grossmann

M

.

The effects of adjuvant endocrine therapy on bone health in women with breast cancer

.

J Endocrinol

.

2019

;

241

(

3

):

R111

–

24

.

77.

Mauras

N

,

de Pijem

LG

,

Hsiang

HY

,

Desrosiers

P

,

Rapaport

R

,

David Schwartz

I

,

Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years

.

J Clin Endocrinol Metab

.

2008

;

93

(

3

):

823

–

31

.

78.

Mauras

N

,

Ross

JL

,

Gagliardi

P

,

Yu

YM

,

Hossain

J

,

Permuy

J

,

Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature

.

J Clin Endocrinol Metab

.

2016

;

101

(

12

):

4984

–

93

.

79.

Hero

M

,

Tommiska

J

,

Vaaralahti

K

,

Laitinen

E-M

,

Sipilä

I

,

Puhakka

L

,

Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B

.

Fertil Steril

.

2012

;

97

(

5

):

1242

–

7

.

80.

Salehpour

S

,

Alipour

P

,

Razzaghy-Azar

M

,

Ardeshirpour

L

,

Shamshiri

A

,

Monfared

MF

,

A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature

.

Horm Res Paediatr

.

2010

;

74

(

6

):

428

–

35

.

81.

Shams

K

,

Cameo

T

,

Fennoy

I

,

Hassoun

AA

,

Lerner

SE

,

Aranoff

GS

,

Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review

.

J Pediatr Endocrinol Metab

.

2014

;

27

(

7–8

):

725

–

30

.

https://doi.org/10.1515/jpem-2016-0219

82.

Ferris

JA

,

Geffner

ME

.

Are aromatase inhibitors in boys with predicted short stature and/or rapidly advancing bone age effective and safe?

J Pediatr Endocrinol Metab

.

2017

;

30

(

3

):

311

–

7

.

.

https://doi.org/10.1210/jc.2005-1392

83.

Hero

M

,

Norjavaara

E

,

Dunkel

L

.

Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial

.

J Clin Endocrinol Metab

.

2005

;

90

(

12

):

6396

–

402

.

.

84.

Mauras

N

,

Bell

J

,

Snow

BG

,

Winslow

KL

.

Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls

.

Fertil Steril

.

2005

;

84

(

1

):

239

–

42

.

85.

Shulman

DI

,

Francis

GL

,

Palmert

MR

,

Eugster

EA

;

Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee

.

Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development

.

Pediatrics

.

2008

;

121

(

4

):

e975

–

83

.

https://doi.org/10.4158/EP.14.2.143

86.

Rosenfeld

RG

,

Bakker

B

.

Compliance and persistence in pediatric and adult patients receiving growth hormone therapy

.

Endocr Pract

.

2008

;

14

(

2

):

143

–

54

.

.

87.

Farfel

A

,

Shalitin

S

,

Morag

N

,

Meyerovitch

J

.

Long-term adherence to growth hormone therapy in a large health maintenance organization cohort

.

Growth Horm IGF Res

.

2019

;

44

:

1

–

5

.

88.

Cutfield

WS

,

Derraik

JGB

,

Gunn

AJ

,

Reid

K

,

Delany

T

,

Robinson

E

,

Non-compliance with growth hormone treatment in children is common and impairs linear growth

.

PLoS One

.

2011

;

6

(

1

):

e16223

.

https://doi.org/10.1159/000437305

89.

Lass

N

,

Reinehr

T

.

Low treatment adherence in pubertal children treated with thyroxin or growth hormone

.

Horm Res Paediatr

.

2015

;

84

(

4

):

240

–

7

.

.

90.

Kapoor

RR

,

Burke

SA

,

Sparrow

SE

,

Hughes

IA

,

Dunger

DB

,

Ong

KK

,

Monitoring of concordance in growth hormone therapy

.

Arch Dis Child

.

2008

;

93

(

2

):

147

–

8

.

91.

De Pedro

S

,

Murillo

M

,

Salinas

I

,

Granada

M-L

,

Martinez

M

,

Puig-Domingo

M

,

Variability in adherence to rhGH treatment: socioeconomic causes and effect on children’s growth

.

Growth Horm IGF Res

.

2016

;

26

:

32

–

5

.

https://doi.org/10.1210/clinem/dgz149

92.

Miller

BS

,

Velazquez

E

,

Yuen

KCJ

.

Long-acting growth hormone preparations – current status and future considerations

.

J Clin Endocrinol Metab

.

2020

;

105

(

6

):

e2121

–

33

.

.

https://doi.org/10.1136/adc.54.8.609

93.

Lippe

B

,

Frasier

SD

,

Kaplan

SA

.

Use of growth hormone-gel

.

Arch Dis Child

.

1979

;

54

(

8

):

609

–

13

.

.

94.

Khadilkar

V

,

Radjuk

KA

,

Bolshova

E

,

Khadgawat

R

,

El Kholy

M

,

Desai

M

,

24-Month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency

.

J Clin Endocrinol Metab

.

2014

;

99

(

1

):

126

–

32

.

95.

Luo

X

,

Hou

L

,

Liang

L

,

Dong

G

,

Shen

S

,

Zhao

Z

,

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

.

Eur J Endocrinol

.

2017

;

177

(

2

):

195

–

205

.

96.

Thornton

PS

,

Maniatis

AK

,

Aghajanova

E

,

Chertok

E

,

Vlachopapadopoulou

E

,

Lin

Z

,

Weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency: the phase 3 heiGHt trial

.

J Clin Endocrinol Metab

.

2021

;

106

(

11

):

3184

–

95

.

97.

Deal

CL

,

Pastrak

A

,

Silverman

LA

,

Rao Valluri

S

,

Wajnrajch

MP

,

Cara

JF

.

OR10-06 somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric phase 3 clinical trial

.

J Endocr Soc

.

2020

;

4

(

Suppl_1

):

OR10-06

.

98.

Sävendahl

L

,

Battelino

T

,

Brod

M

,

Højby Rasmussen

M

,

Horikawa

R

,

Vestergaard Juul

R

,

Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial

.

J Clin Endocrinol Metab

.

2020

;

105

(

4

):

e1847

–

61

.

99.

Blum

WF

,

Bright

GM

,

Do

M-HT

,

McKew

JC

,

Chen

H

,

Thorner

MO

.

Corroboration of height velocity prediction markers for rhGH with an oral GH secretagogue treatment in children with GHD

.

J Endocr Soc

.

2021

;

5

(

6

):

bvab029

.

100.

Bright

GM

,

Do

M-HT

,

McKew

JC

,

Blum

WF

,

Thorner

MO

.

Development of a predictive enrichment marker for the oral GH secretagogue LUM-201 in pediatric growth hormone deficiency

.

J Endocr Soc

.

2021

;

5

(

6

):

bvab030

.

101.

Hirota

K

,

Furuya

M

,

Morozumi

N

,

Yoshikiyo

K

,

Yotsumoto

T

,

Jindo

T

,

Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats

.

PLoS One

.

2018

;

13

(

9

):

e0204172

.

102.

Wang

SR

,

Amano

N

,

Docko

AJ

,

Funari

MFA

,

Quedas

EPS

,

Nishi

MY

,

Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature

.

Hum Mutat

.

2015

;

36

(

4

):

474

–

81

.

103.

Hisado-Oliva

A

,

Garre-Vázquez

AI

,

Santaolalla-Caballero

F

,

Belinchón

A

,

Barreda-Bonis

AC

,

Vasques

GA

,

Heterozygous NPR2 mutations cause disproportionate short stature, similar to Léri-Weill dyschondrosteosis

.

J Clin Endocrinol Metab

.

2015

;

100

(

8

):

E1133

–

42

.

104.

Wendt

DJ

,

Dvorak-Ewell

M

,

Bullens

S

,

Lorget

F

,

Bell

SM

,

Peng

J

,

Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism

.

J Pharmacol Exp Ther

.

2015

;

353

(

1

):

132

–

49

.

105.

Savarirayan

R

,

Irving

M

,

Bacino

CA

,

Bostwick

B

,

Charrow

J

,

Cormier-Daire

V

,

C-type natriuretic peptide analogue therapy in children with achondroplasia

.

N Engl J Med

.

2019

;

381

(

1

):

25

–

35

.

106.

Savarirayan

R

,

Tofts

L

,

Irving

M

,

Wilcox

W

,

Bacino

CA

,

Hoover-Fong

J

,

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

.

Lancet

.

2020

;

396

(

10252

):

684

–

92

.

107.

Savarirayan

R

,

Tofts

L

,

Irving

M

,

Wilcox

WR

,

Bacino

CA

,

Hoover-Fong

J

,

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

.

Genet Med

.

2021

;

23

:

2443

–

7

.

108.

Gonçalves

D

,

Rignol

G

,

Dellugat

P

,

Hartmann

G

,

Garcia

SS

,

Stavenhagen

J

,

In vitro and in vivo characterization of recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia

.

PLoS One

.

2020

;

15

(

12

):

e0244368

.

109.

Komla-Ebri

D

,

Dambroise

E

,

Kramer

I

,

Benoist-Lasselin

C

,

Kaci

N

,

Le Gall

C

,

Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model

.

J Clin Invest

.

2016

;

126

(

5

):

1871

–

84

.